Internal Medicine, Hematology & Oncology · Buffalo, NY
NPI
1568405868
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
Elm and Carlton St
Buffalo, NY, 14263
Phone (716) 845-2300
Groups this clinician bills Medicare through
Medicare paid, 2024
$16K
262 services
Medicare patients, 2024
85
Average age 71
Drug cost, 2024
$6.3M
665 prescriptions
Company payments, 2025
$43.25
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James E Thompson was code 99232 (hospital e&m - subsequent), 98 times for 27 patients. In total James E Thompson billed 262 services in 20 codes, and Medicare paid $16K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-02-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 98 | 27 | $59.18 | $5,800 |
| 99231 Hospital E&M - Subsequent | Facility | 35 | 19 | $37.03 | $1,296 |
| 99214 Office E&M - Established | Facility | 32 | 24 | $70.85 | $2,267 |
| 99233 Hospital E&M - Subsequent | Facility | 21 | 16 | $89.01 | $1,869 |
| 99215 Office E&M - Established | Facility | 16 | 13 | $108.39 | $1,734 |
| 38222 Other Organ Systems | Facility | 15 | 13 | $55.97 | $840 |
By year: 2022 $18K for 297 services; 2023 $13K for 205 services; 2024 $16K for 262 services.
Medicare prescription drug claims, 2024
In 2024, the drug James E Thompson prescribed most often to Medicare patients was Imatinib Mesylate, with 99 prescriptions and refills. In total James E Thompson wrote 665 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imatinib Mesylate Generic | 99 | 99 | Under 11 | $129K |
| Sprycel Dasatinib | 89 | 93 | 16 | $1.2M |
| Hydroxyurea Generic | 81 | 122 | 14 | $1,734 |
| Bosulif Bosutinib | 80 | 80 | Under 11 | $856K |
| Inqovi Decitabine/Cedazuridine | 46 | 46 | Under 11 | $365K |
| Scemblix Asciminib Hydrochloride | 32 | 33 | Under 11 | $651K |
| Iclusig Ponatinib Hcl | 27 | 27 | Under 11 | $585K |
| Venclexta Venetoclax | 25 | 25 | Under 11 | $74K |
| Jakafi Ruxolitinib Phosphate | 24 | 24 | Under 11 | $394K |
| Methotrexate Methotrexate Sodium | 22 | 48 | Under 11 | $992 |
| Ojjaara Momelotinib Dihydrochloride | 21 | 21 | Under 11 | $579K |
| Dasatinib Generic | 20 | 22 | Under 11 | $162K |
| Ayvakit Avapritinib | 12 | 12 | Under 11 | $458K |
| Vonjo Pacritinib Citrate | 11 | 11 | Under 11 | $220K |
Brand drugs: 412 claims; generic drugs: 253 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James E Thompson $43.25 ($43.25 in general payments such as food, travel and fees) from 3 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $43.25.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 1 | $43.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.